Article
Liquid biopsy for KRAS, NRAS and BRAF mutation testing in advanced colorectal cancer patients: the Argentinean experience.
Future oncology (London, England) - 1 Sept 2022
Güttlein Leandro, Luca María R, Esteso Federico, Fresno Cristóbal, Mariani Javier, Otero Pizarro Mercedes, Brest Esteban, Starapoli Solange, Kreimberg Kevin, Teves Paula, Mendoza Bertelli Andrea, R Girotti María, Salanova Ruben, O'Connor Juan M
Abstract excerpt
Objective: To analyze the frequency of KRAS, NRAS and BRAF hotspot mutations in circulating tumor DNA (ctDNA) from patients with metastatic colorectal cancer (mCRC). Methods: Observational, descriptive and retrospective study in mCRC patients with available ctDNA-based genotype of KRAS, NRAS and BRAF. Results: The frequencies of plasma mutations for KRAS, NRAS and BRAF were 34% (± 7), 4% (± 3) and 4% (± 3),...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.